The future of RNA therapeutics represents one of the most promising, transformative, and lucrative frontiers in modern global healthcare and biotechnology. Following the massive, unprecedented success of mRNA vaccines during global health crises, pharmaceutical titans and innovative biotech startups are aggressively expanding RNA technology to treat a vast array of previously untreatable conditions. The market is projected to experience exponential growth as researchers perfect advanced delivery mechanisms—such as lipid nanoparticles and antibody-oligonucleotide conjugates—that allow genetic medicines to precisely target specific tissues, muscles, and organs. In the coming decades, RNA interference (RNAi), antisense oligonucleotides, and CRISPR-associated RNA therapies will move beyond rare genetic and neuromuscular disorders, offering revolutionary personalized treatments for widespread chronic ailments, cardiovascular diseases, and complex aggressive oncological indications.